We recently succeeded in purifying a monocyte chemotactic factor (MCF) from the conditioned media of a myelomonocytic cell line (THP-1) (1). We have molecularly cloned the cDNA of MCF (2), and shown that MCF, in addition to its monocyte chemotactic activity, also activates monocytes to be more cytostatic against several types ofhuman tumor cells in vitro (1) . Therefore, we termed this molecule monocyte chemotactic and activating factor (MCAF). Subsequently, MCAF has been shown to be produced by several additional cell types, namely fibroblasts and endothelial cells (3) . We describe here that MCAF, which was purified from human fibrosarcoma cell line-conditioned media, also induces superoxide anion and lysosomal enzyme release from human monocytes and has potent in vivo monocyte recruitment activity.
Results
Purification of MCAF. MCAF was purified to homogeneity from eight liters of conditioned media from a TNFstimulated fibrosarcoma cell line, 8387, by sequential chromatography, including heparin-Sepharose affinity chromatography, gel filtration, carboxymethyl (CM)-HPLC, and reverse-phase (RP)-HPLC. The biological activities ofeach fraction was monitored by both in vitro monocyte chemotactic activity and (3-glucosaminidase-releasing activity. On C M-HPLC, MCAF was eluted at -0.3 NaCl, corresponding to two distinct peaks (CM fractions 25 and 26, data not shown). MCAF from each fraction was applied to RP-HPLC . As shown in Fig.  1 , a and b, monocyte chemotactic activity and R-glucosaminidase-releasing activity coeluted at a discrete absorbance peak located in both RP-HPLC eluates . We have also confirmed that these two activities coeluted with monocyte cytostatic augmenting activity (RP-HPLC ; Fig . 1 ), suggesting that all these activities are due to a single molecular species . SDS-PAGE analysis ofthe purified MCAF showed microheterogeneity in molecular mass at -15 kD (Fig. 1 c) . As shown in Fig . 1 d, all bands detected on SDS-PAGE analysis showed the immunological reactivity with MCAF on Western-blotting analysis. No endotoxin activity was detected by Limulus lysate assay (<0 .05 ng/ml) . Fractions from CM 25, RP 21-22 contained 10.6 pg protein, and fractions from CM 26, RP 22-23 contained 6.8 leg protein, based on amino acid composition analysis .
The identity ofthe purified MCAF from a human fibrosarcoma cell line with the previously purified MCAF from a human myelomonocytic cell line, THP-1, was further supported by specific inhibition of binding at 37°C of 125 I-labeled MCAF obtained from THP-1 to human PBMC by the unlabeled fibrosarcoma-derived MCAF (Fig.  2) . Another basic polypeptide chemoattractant, IL-8, at concentrations from 0.1 ng/ml to 10 Ag/ml, failed to inhibit the binding of 125 I-labeled MCAF to human PBMC at 37°C .
In Vitro and In Vivo Biological Activities of Purled MCAF. The purified MCAF from fraction CM 25, RP 21-22 and fraction CM 26, RP 22-23 was assayed for monocyte chemotactic activity, N-acetyl a-glucosaminidase release, and superoxide anion release. The half-maximal monocyte chemotactic response occurred at doses of ti 1 ng/ml for both fractions, while the N-acetyl (3-glucosaminidase release showed an EC5o of -3-5 ng/ml (data not shown) . MCAF was able to release superoxide anions at concentrations >20 ng/ml. MCAF exhibited no chemotactic activity for neutrophils at any concentration tested (data not shown) .
To evaluate whether the purified MCAF also had in vivo cell recruitment effects, serial dilutions of MCAF in endotoxin-free PBS (fraction CM 25, RP 21-22) were injected into the ears of Lewis rats at various times . MCAF showed selective monocyte/macrophage recruitment activity in vivo when assayed at 3, 6, and 18 h. There was a significant dose-and time-dependent accumulation of total leukocytes in the perivenular connective tissue underlying the intradermal injection sites of purified MCAF in the ears of Lewis rats . Dose-dependent accumulation was found for monocyte/macrophages (p = 0.002) but not for neutrophils (p = 0.18) or lymphocytes (p = 0.14) at each of the time points tested (data not shown) . No monocyte infiltration was detected at 3 min, 30 min, or 90 min after injection, regardless of the dose of purified MCAF used (data not shown) . Fig. 3 A shows the site of PBS injection at 18 h to contain a significant macrophage infiltrate, but a sparse infiltration of lymphocytes and neutrophils. Fig. 3 B shows that 5.3 ng/ml of MCAF induced a much more marked monocyte/macrophage infiltration at 18 h. 
1 Discussion
It is well established that a large number of tumors are infiltrated with macrophages (9) . The macrophages may either stimulate tumor growth through the production of growth factors or exert a suppressive effect through the production of "macrophage-activating factors," such as IFN-(3, TNF, IL-1, and MCAF. A number oftumor-derived cell lines have been shown to produce monocyte chemotactic factors such as MCAF and related mediators (4). Such tumors are often infiltrated with macrophages in vivo, which is associated with a better prognosis (4) . MCAF may contribute to inhibiting tumor growth by macrophages by attracting them to the tumor site and subsequently activating increased cytostatic activity. Since IL-1 and TNF induce MCAF production by certain tumor types as well as by normal fibroblasts and endothelial cells (3), the regulation of MCAF production in tumor cells, as well as in the connective tissues surrounding the tumor, may be regulated by locally produced IL-1 and TNF . Even though MCAF, unlike other cytokines such as IFN-y and TNF, does not have a direct cytotoxic or cytostatic effect on tumor cells, MCAF may play an important role in control of local tumor growth either by its effect on monocytes or possibly by inducing other cytokines.
In this report, we have shown that MCAF induced N-acetyl /3-D-glucosaminidase and superoxide release, supporting the concept that MCAF is not merely a chemoattractant for monocytes. Although the mechanism of augmentation of monocyte cytostatic activity against tumor cells by MCAF is not yet known, it may be mediated by lysosomal enzyme and/or superoxide anion release. IL-6, IL-1, and TNF are not responsible for this activity of MCAF, since MCAF does not induce mRNA expression for IL-1-a/(3 or TNFac in monocytes in vitro, and antibodies to TNF, and IL-6 did not block the cytostatic effect of MCAF (1) .
We are also the first to show that MCAF has potent monocyte recruitment activity in vivo. This observation is consistent with and provides an explanation for previous reports of a correlation between monocyte chemotactic activity and macrophage content oftumors (4) . Monocyte accumulation at the injection site ofMCAF starts gradually at 3 h and increases up to 18 h. The potent in vivo monocyte recruitment activity of MCAF supports the hypothesis that MCAF is involved in the recruitment of monocytes to delayed-type hypersensitivity reaction sites.
We have also shown the specific binding of 125I-MCAF to human PBMC at 37°C. Interestingly, another recently cloned chemoattractant, IL-8 (6), which has similar biochemical characteristics, did not compete with 125 1-MCAF in binding to monocyte-enriched mononuclear cells, suggesting that there are distinct receptors for MCAF on human monocytes. The binding of 125 1-MCAF does not occur at 4°C, but at 37°C, and starts rapidly with maximal binding after 15 min. The bound molecules are immediately internalized, as judged by treating cells with 0.1 M glycine-HCI, pH 3 .0, 0.15 M NaCl buffered solution . This internalization can not be blocked by either ATP synthesis inhibitors (sodium azide; 2-4, dinitrophenol) or by transglutaminase inhibitors (bacitracin, monodansyl cadaverine). These phenomena are unusual for a polypeptide receptor, and, therefore, we have been unable to estimate the number or the binding affinity of the receptor for MCAF on any cell type . Summary A monocyte chemotactic and activating factor (MCAF) has been purified from TNFstimulated 8387 human fibrosarcoma cell line-conditioned media. The purified MCAF showed microheterogeneity yielding two bands on SDS-PAGE analysis. Fibrosarcoma-derived MCAF specifically competed with THP-1 (a human monocytic cell line)-derived 125 1-labeled MCAF in binding to human PBMC, whereas a similar basic heparin-binding leukocyte chemoattractant, IL-8, did not . The purified MCAF stimulated superoxide anion and N-acetyl j3-D glucosaminidase-releasing activity in human monocytes, as well as monocyte cytostatic augmenting activity against tumor cells and chemotactic activity for monocytes . When injected subcutaneously into Lewis rat ears, the purified human MCAF also induced considerable in vivo local monocyte infiltration beginning at 3 h and becoming maximal at 18 h. In conclusion, the data presented in this paper indicate that MCAF is a potent activator ofmonocytes as well as a monocyte recruitment factorthat acts through receptors that are specific for this novel molecule. This novel cytokine might have an important role in tumor growth control due to its ability to attract and activate monocytes.
